Investigation of Therapeutic Efficacy of Intravesical Tigecycline Administration in Rats with Cystitis Induced by Extensively Drug-Resistant (XDR), Tigecycline-Sensitive Acinetobacter baumannii Strain.

IF 4.3 2区医学 Q1 INFECTIOUS DISEASES

Antibiotics-Basel Pub Date : 2025-06-16 DOI:10.3390/antibiotics14060611

Cihan Yüksel, Işıl D Alıravcı, Murat Koşan, Sinem Esen, Sevinç Yenice Aktaş, Neslihan Kaya Terzi, Ahmet Ali Berber, Sevil Alkan, Selçuk Kaya

{"title":"Investigation of Therapeutic Efficacy of Intravesical Tigecycline Administration in Rats with Cystitis Induced by Extensively Drug-Resistant (XDR), Tigecycline-Sensitive Acinetobacter baumannii Strain.","authors":"Cihan Yüksel, Işıl D Alıravcı, Murat Koşan, Sinem Esen, Sevinç Yenice Aktaş, Neslihan Kaya Terzi, Ahmet Ali Berber, Sevil Alkan, Selçuk Kaya","doi":"10.3390/antibiotics14060611","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to evaluate the therapeutic efficacy of intravesical tigecycline administration in a rat model of cystitis induced by a tigecycline-sensitive, extensively drug-resistant (XDR) Acinetobacter baumannii strain.Methods: Thirty-six female Wistar albino rats were inoculated intravesically with XDR A. baumannii to induce cystitis. Twenty-four rats that developed infection were divided into four groups: untreated control, saline irrigation, low-dose tigecycline (6.25 mg/kg), and high-dose tigecycline (25 mg/kg). Microbiological clearance was assessed via urine cultures on days 3 and 5. Bladder tissues were analyzed histopathologically and for genotoxicity using the Comet assay.Results: On day 5, microbiological clearance was significantly higher in tigecycline-treated groups compared to controls (p = 0.028). Histopathology revealed significantly more inflammation in the high-dose tigecycline group (p = 0.029). Genotoxicity was observed in both tigecycline groups, independent of dose (p < 0.05).Conclusions: Intravesical tigecycline demonstrated microbiological efficacy against XDR A. baumannii-induced cystitis. However, its inflammatory and genotoxic potential necessitates further preclinical evaluation.","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"14 6","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189304/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics14060611","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to evaluate the therapeutic efficacy of intravesical tigecycline administration in a rat model of cystitis induced by a tigecycline-sensitive, extensively drug-resistant (XDR) Acinetobacter baumannii strain.

Methods: Thirty-six female Wistar albino rats were inoculated intravesically with XDR A. baumannii to induce cystitis. Twenty-four rats that developed infection were divided into four groups: untreated control, saline irrigation, low-dose tigecycline (6.25 mg/kg), and high-dose tigecycline (25 mg/kg). Microbiological clearance was assessed via urine cultures on days 3 and 5. Bladder tissues were analyzed histopathologically and for genotoxicity using the Comet assay.

Results: On day 5, microbiological clearance was significantly higher in tigecycline-treated groups compared to controls (p = 0.028). Histopathology revealed significantly more inflammation in the high-dose tigecycline group (p = 0.029). Genotoxicity was observed in both tigecycline groups, independent of dose (p < 0.05).

Conclusions: Intravesical tigecycline demonstrated microbiological efficacy against XDR A. baumannii-induced cystitis. However, its inflammatory and genotoxic potential necessitates further preclinical evaluation.

查看原文本刊更多论文

膀胱内给药替加环素治疗广泛耐药（XDR）、替加环素敏感鲍曼不动杆菌引起的膀胱炎的疗效研究。

背景：本研究旨在评价膀胱内给药替加环素对替加环素敏感、广泛耐药（XDR）鲍曼不动杆菌引起的大鼠膀胱炎模型的治疗效果。方法：对36只雌性Wistar白化大鼠进行XDR鲍曼杆菌免疫诱导膀胱炎。将24只发生感染的大鼠分为未处理对照组、生理盐水冲洗组、低剂量替加环素组（6.25 mg/kg）和高剂量替加环素组（25 mg/kg）。在第3天和第5天通过尿液培养评估微生物清除率。膀胱组织组织病理学分析和遗传毒性使用彗星试验。结果：第5天，替加环素治疗组的微生物清除率显著高于对照组（p = 0.028）。组织病理学显示，大剂量替加环素组炎症明显加重（p = 0.029）。两个替加环素组均有遗传毒性，且与剂量无关（p < 0.05）。结论：膀胱内注射替加环素对XDR鲍曼杆菌引起的膀胱炎具有微生物学疗效。然而，其潜在的炎症和遗传毒性需要进一步的临床前评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antibiotics-Basel Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics

CiteScore

7.30

自引率

14.60%

发文量

1547

审稿时长

11 weeks

期刊介绍： Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.